Recruiting

OSEM

Sponsor:

UNCANCER LLC

Code:

NCT07885033

Conditions

Head and Neck Cancer (H&N)

Oral Mucositis (Ulcerative) Due to Radiation

Stomatitis (Oral Mucositis)

Xerostomia Due to Radiotherapy

Radiation Toxicity

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ORAL CARE PRODUCT KIT

Study Details

Brief summary:

People having radiation therapy to the head and neck often develop painful mouth problems - mouth sores, dry mouth, mouth pain, trouble eating and drinking, and changes in taste. These problems can become severe enough to interrupt radiation treatment or lead to an emergency room visit or a hospital stay.

This study is testing whether an oral care program called OSEM (Oral Side-Effect Management) reduces how severe those mouth problems become.

Fifty adults starting radiation to a head and neck site at Premier Cancer Center will take part. Each person will be assigned by chance, like a coin toss, to one of two groups:

One group receives the Peace of Mouth Kit - everyday mouth care products including dry mouth candies, ginger candies for nausea, a mouth rinse, a sensitivity toothpaste, a soft toothbrush and a lip balm - together with a short check-in each week with a member of the Premier team right after their radiation treatment.

The other group receives their usual care at Premier, unchanged.

Everyone in the study fills out the same short questionnaire about their mouth each week during radiation, and once more about four weeks after their last treatment. Everyone continues to see their radiation doctor every week, exactly as they would if they were not in the study.

Taking part lasts about 11 weeks in all.

The items in the kit are everyday consumer mouth care products. They are not medicines of any kind, and the U.S. Food and Drug Administration has not approved them to treat or prevent any disease.

Conditions

Head and Neck Cancer (H&N)

Oral Mucositis (Ulcerative) Due to Radiation

Stomatitis (Oral Mucositis)

Xerostomia Due to Radiotherapy

Radiation Toxicity

Study ID

NCT07885033

Start date

Nov, 2026

Status verified date

Nov, 2026

Completion date

Dec, 2027

Anticipated

Primary completion date

Aug, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Adults aged 18 years or older Histologically confirmed malignancy of a head and neck site Planned definitive or post-operative external beam radiation therapy to a head and neck site, delivered at Premier Cancer Center Planned course of at least 20 fractions over approximately 4 to 7 weeks With or without concurrent systemic therapy Able to provide written informed consent Able to complete an electronic questionnaire in English, with or without assistance

Exclusion Criteria:

Palliative short-course radiation, or a planned course of fewer than 20 fractions Re-irradiation of a previously irradiated head and neck field Radiation delivered at an institution other than Premier Known allergy or sensitivity to any component of the Peace of Mouth Kit Any condition that, in the judgment of the treating radiation oncologist or the Premier Physician of Record, makes participation unsafe or impracticable Inability to complete study assessments

Study Design

Enrollment

50 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: OSEM Program

Participants receive the Peace of Mouth Kit at enrollment, at approximately week 5, and at the final treatment visit in week 7 - three kits in total - together with a structured review by the Premier clinical coordinator each week, immediately after radiation treatment.

The weekly review consists of a fixed set of safety-flag questions, review of the participant's weekly symptom band and red-flag status, and assessment of kit use. Where the band or a red-flag criterion indicates it, the coordinator escalates directly to the on-call Premier radiation oncologist, who determines clinical management. The study does not direct clinical management.

Premier standard of care continues unchanged, including the weekly radiation oncologist assessment and the after-hours on-call service.

no intervention: STANDARD OF CARE

Participants receive Premier standard of care without modification, including the weekly radiation oncologist assessment, the after-hours on-call service, and any supportive-care measure the treating team judges appropriate.

Participants complete the same baseline and weekly symptom questionnaire as the intervention arm, for research purposes only. The resulting symptom band is computed and retained for analysis but is not reviewed for escalation, is not returned to anyone, and does not generate any contact. There is no kit, no clinical coordinator review and no safety-flag questions.

Kit components and equivalent products remain commercially available, and nothing is withheld from participants in this arm.

Interventions

ORAL CARE PRODUCT KIT

A kit of six commercially available consumer oral care products, supplied at enrollment, at approximately week 5, and at the final treatment visit in week 7 - three kits in total, each a one-month supply.

Each kit contains: dry mouth candies, 6 packs, xylitol-based, 3 lemon and 3 sour cherry; nausea candies, 1 pack, ginger, xylitol-based; soothing mouth rinse, 30 single-dose stick packs of sodium chloride and sodium bicarbonate, one per day; sensitivity toothpaste with 10% nano-hydroxyapatite and xylitol, 3 oz; a soft bamboo-handled toothbrush; and a lip balm. A reusable bottle for preparing the daily rinse comes with the first kit only.

Use is at the participant's discretion, following written instructions in each kit. Participants may stop any component at any time and are told to do so if it causes discomfort.

No component is a prescription or over-the-counter drug, and none is FDA-approved to treat or prevent any disease.

Primary outcome measure

  • Oral symptom burden: area under the weekly oral symptom score curve [ Time Frame: From the first delivered radiation fraction (Time 0) through the end-of-treatment assessment, up to 7 weeks and the a 4 week end of trial follow up. ]

Central Contacts and Locations

Central contacts

Locations

Premier Cancer Center

Recruiting

Clearwater, Florida, United States, 33765-1703

Contacts

OSEM Study Coordinator

844-806-0124osem@uncancer.com

More Information

Sponsor

UNCANCER LLC

Last update posted

Nov 16, 2026

Last verified

Nov, 2026

Keywords

  • oncology side-effect management pilot study

Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-17. This information was provided to ClinicalTrials.gov by UNCANCER LLC on 2026-11-16. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.